This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The NAMSAL ANRS 12313 Study Group. N. Engl. J. Med. 381, 816–826 (2019).
Shafer R. In 30th International Workshop on HIV Drug Resistance and Treatment Strategies https://go.nature.com/47BYRUZ (2023).
Tao, K. et al. Viruses 15, 1932 (2023).
Xiao, M. A. et al. Antimicrob. Agents Chemother. 67, e0138622 (2023).
Brenner, B. G. et al. J. Antimicrob. Chemother. 71, 1948–1953 (2016).
Loosli, T. et al. Lancet HIV 10, e733–e741 (2023).
Fokam, J. et al. Antimicrob. Resist. Infect. Control 9, 143 (2020).
Fokam, J. et al. In 3rd Conf. Public Health in Africa (CPHIA) abstract 2883 (2023).
Lübke, N. et al. N. Engl. J. Med. 381, 887–889 (2019).
Dorward, J. et al. Lancet HIV 5, e400–e404 (2018).
Acknowledgements
N.N. is supported by the US NIH/NIAID R01 AI147331-02 and J.F. is supported by EDCTP RIA2020-EF3000.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.-F.P. has participated in boards, gave speeches at sponsored events, and/or received grants from Gilead, ViiV, GSK, Janssen, Astra Zeneca, Merck and Pfizer.
Rights and permissions
About this article
Cite this article
Fokam, J., Inzaule, S., Colizzi, V. et al. HIV drug resistance to integrase inhibitors in low- and middle-income countries. Nat Med 30, 618–619 (2024). https://doi.org/10.1038/s41591-023-02763-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02763-0